CT-P10

December 14, 2018

Truxima Shows Safety, Efficacy Comparable to Rituxan in Advanced Follicular Lymphoma

News

Truxima (rituximab-abbs), a biosimilar to Rituxan (rituxumab), has similar safety and efficacy as the original product in patients with advanced follicular lymphoma after two years, results from a Phase 3 ... Read more

October 15, 2018

FDA Committee Recommends Truxima’s Approval for 3 Non-Hodgkin’s Lymphoma Indications

News

Truxima (CT-P10) a biosimilar to Rituxan (rituximab), has been unanimously recommended for approval by the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee for the treatment of three non-Hodgkin’s lymphoma (NHL) indications, ... Read more

July 11, 2017

FDA Will Review Application Seeking Approval of Truxima for Same Indications as Rituxan

News

The U.S. Food and Drug Administration has accepted for review the biologics license application (BLA) requesting the approval of Truxima (CT-P10), a biosimilar to Rituxan (rituximab), for the treatment of ... Read more

June 23, 2017June 23, 2017

Truxima Shows Similar Safety and Efficacy Results to Rituxan in Phase 3 Trial

News

Results from a Phase 3 trial have shown that Truxima (CT-P10), developed by Celltrion Healthcare, has a similar efficacy and safety profile as Genetech’s Rituxan (rituximab) for the treatment of advanced-stage follicular lymphoma. ... Read more